Onsdag 28 Oktober | 20:05:00 Europe / Stockholm
Est. tid*
2026-08-28 - Kvartalsrapport 2026-Q2
2026-05-30 - Årsstämma
2026-04-29 - Bokslutskommuniké 2025
2025-08-28 - Kvartalsrapport 2025-Q2
2025-06-02 - X-dag ordinarie utdelning BRAINP 0.00 DKK
2025-05-29 - Årsstämma
2025-04-29 - Bokslutskommuniké 2024
2025-02-12 - Extra Bolagsstämma 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning BRAINP 0.00 DKK
2024-05-15 - Årsstämma
2024-05-07 - Bokslutskommuniké 2023
2023-10-11 - Extra Bolagsstämma 2023
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-30 - X-dag ordinarie utdelning BRAINP 0.00 DKK
2023-05-26 - Årsstämma
2023-04-28 - Bokslutskommuniké 2022
2022-09-29 - Kvartalsrapport 2022-Q2
2022-09-02 - Extra Bolagsstämma 2022
2022-05-19 - X-dag ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 - Årsstämma
2022-04-29 - Bokslutskommuniké 2021
LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriVård & Omsorg
Brain+ är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av behandling för demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa. Brain+ har sitt huvudkontor i Köpenhamn.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Brain+ announces registration of directed issue with the Danish Business Authority

2024-04-11 10:08:45
Copenhagen, Denmark, April 10, 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · New shares from the directed issue to guarantors of the series TO 3 warrant exercise have been registered with the Danish Business Authority (DA: Erhvervsstyrelsen) · The new shares are expected to commence trading on Nasdaq First North Copenhagen on April 12, 2024

On March 26, 2024, Brain+ A/S (“Brain+” or “the Company”) announced the outcome of the exercise of warrants of series TO 3 (the “Warrants”), which were issued in connection with the Company’s unit rights issue in May 2023. In connection with the Warrants exercise, Brain+ also carried out a directed issue to guarantors of the Warrants exercise (the “Directed Issue”). The new shares from the Directed Issue have now been registered with the Danish Business Authority.

The new shares from the Directed Issue to the guarantors of the Warrants exercise have now been registered with the Danish Business Authority. The registration of shares issued from the exercise of Warrants was announced by Brain+ on April 10, 2024. Upon registration of the shares from the Directed Issue, the number of shares in Brain+ has increased with 7,787,874 shares, from 83,661,405 shares to 91,449,279 shares, and the Company’s nominal share capital has increased by DKK 778,787.40, from DKK 8,366,140.50 to DKK 9,144,927.90.

Application has been made to Nasdaq Copenhagen A/S for the new shares to be admitted for trading on Nasdaq First North Copenhagen. It is expected that the first day of trading of the new shares from the Directed Issue will be on April 12, 2024.

Advisors
In connection with the unit rights issue including the issue and exercise of warrants of series TO 3, Sedermera Corporate Finance AB and Gemstone Capital A/S have acted as financial advisors to Brain+. Markets & Corporate Law Nordic AB acted as legal advisor. Nordic Issuing AB is the issuing agent.

For more information about the warrant exercise, please contact:

Sedermera Corporate Finance AB
Phone: +46 (0) 40 615 14 10

E-mail: cf@sedermera.se
www.sedermera.se

Gemstone Capital A/S
Phone: +45 33 22 07 00

E-mail: sh@gemstonecapital.com
www.gemstonecapital.com

For more information about Brain+, please contact:

Kim Baden-Kristensen, CEO
Phone: +45 31 39 33 17

E-mail: kim@brain-plus.com
www.brain-plus.com

Certified Adviser

Keswick Global AG
Phone: +43 1 740 408 045

E-mail: info@keswickglobal.com